Idorsia announces
financial results for
the first half of 2021
Idorsia initiates the
Phase 3 registration
study with selatogrel
for AMI
Our key assets have
the potential to
transform treatment in
the target indications...
Idorsia today
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Idorsia People
Idorsia’s success depends on its people.
Target diseases
Idorsia's development compounds target a number of different diseases.
News
| 29 Jul 2021 | |
| 28 Jul 2021 | |
| 28 Jul 2021 |
Events
| Event | When |
| Nine-months 2021 Financial Results reporting* |
October 26, 2021
|
| Full-Year 2021 Financial Results reporting* |
February 8, 2022
|
| First-Quarter 2022 Financial Results reporting* |
April 26, 2022
|
*We will be in a silent period for 10 days ahead of the financial reporting.
Shareprice
Contact
Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland
- +41 58 844 00 00
- Contact us online
- How to get to us